Screener › Biotech Small Cap Stocks
Biotech Small Cap Stocks
Small and micro cap biotech stocks under $5B market cap — high-risk, high-reward pipeline plays in gene therapy, oncology, rare diseases, and precision medicine.
| Ticker | Company | Price | Mkt Cap | Upside | 52W Pos. | Smart Money |
|---|---|---|---|---|---|---|
| STVN | Stevanato Group | $18.03 +1.01% | $4.92B | 37.7% | 34% | — |
| LGND | Ligand Pharmaceuticals | $229.33 +3.22% | $4.6B | 18.5% | 87.8% | — |
| FOLD | Amicus Therapeutics | $14.49 +0% | $4.55B | 0.1% | 99.9% | — |
| TVTX | Travere Therapeutics | $44.43 -0.69% | $4.13B | 20.6% | 88% | — |
| IRTC | iRhythm Technologies | $116.56 -1.11% | $3.83B | 55.2% | 7.5% | — |
| MMSI | Merit Medical Systems | $64.17 +0.85% | $3.83B | 41.2% | 11.8% | — |
| NVST | Envista Holdings | $23.43 -0.85% | $3.81B | 27.4% | 49.7% | — |
| TWST | Twist Bioscience | $60.57 +2.95% | $3.77B | 4.6% | 87.2% | — |
| FIE.DE | Fielmann | $43.90 -0.23% | $3.69B | 31.8% | 21.5% | — |
| ACAD | Acadia Pharmaceuticals | $21.10 -1.03% | $3.61B | 50% | 16.3% | — |
| VKTX | Viking Therapeutics | $30.89 +0.68% | $3.59B | 198.9% | 39.3% | — |
| EWTX | Edgewise Therapeutics | $32.70 +0.03% | $3.52B | 33.5% | 73.9% | — |
| SFZN.SW | Siegfried Holding | $80.25 -0.68% | $3.52B | 29.5% | 35.5% | — |
| ALHC | Alignment Healthcare | $16.35 -0.12% | $3.38B | 53.9% | 38.6% | — |
| VIRP.PA | Virbac | $360.00 -0.55% | $3.02B | 14.7% | 68.4% | — |
| DNLI | Denali Therapeutics | $18.64 -3.42% | $2.96B | 90.1% | 54.2% | — |
| BEAM | Beam Therapeutics | $28.64 +3.51% | $2.95B | 78.3% | 63% | — |
| ARQT | Arcutis Biotherapeutics | $20.86 -0.71% | $2.61B | 66% | 42.7% | — |
| DMP.DE | Dermapharm Holding | $49.40 +0.3% | $2.45B | -3.1% | 87.6% | — |
| CLDX | Celldex Therapeutics | $30.73 +0.49% | $2.41B | 90.1% | 70.6% | — |
| TMDX | TransMedics Group | $68.94 +0.12% | $2.38B | 71% | 9.2% | — |
| NKTR | Nektar Therapeutics | $66.61 -2.87% | $2.25B | 130.1% | 58% | — |
| LMAT | LeMaitre Vascular | $97.75 -1.78% | $2.23B | 21.5% | 48.9% | — |
| ZLAB | Zymeworks | $18.61 -2.57% | $2.09B | 81.5% | 9.3% | — |
| NVCR | NovoCure | $17.96 +0.34% | $2.08B | 46.4% | 79.5% | — |
| OMCL | Omnicell | $44.41 +1.49% | $2.02B | 38% | 62.4% | — |
| ADMA | ADMA Biologics | $8.24 -2.6% | $1.91B | 103.3% | 6.8% | — |
| TECN.SW | Tecan Group | $149.40 +0.95% | $1.89B | 10.9% | 58% | — |
| IOVA | Iovance Biotherapeutics | $4.11 +11.08% | $1.84B | 114.1% | 61.7% | — |
| DVAX | Dynavax Technologies | $15.50 +0% | $1.82B | 3.2% | 50% | — |
| OCUL | Ocular Therapeutix | $8.23 +0.12% | $1.8B | 215.9% | 19.6% | — |
| SRPT | Sarepta Therapeutics | $16.80 -0.94% | $1.77B | 31% | 19% | — |
| UFPT | UFP Technologies | $228.97 +1.27% | $1.77B | 41.7% | 54.5% | — |
| ANAB | AnaptysBio | $59.71 -1.16% | $1.74B | 41.3% | 79.2% | — |
| DRW3.DE | Draegerwerk | $92.30 +0.22% | $1.73B | 5.4% | 80.5% | — |
| AGIO | Agios Pharmaceuticals | $28.14 -2.26% | $1.67B | 46.1% | 24.8% | — |
| INVA | Innoviva | $22.46 +1.17% | $1.66B | 58.1% | 68.8% | — |
| RXRX | Recursion Pharmaceuticals | $3.01 -3.22% | $1.6B | 120.7% | 5.4% | — |
| CMPS | COMPASS Pathways | $11.81 +1.9% | $1.59B | 90.5% | 95.7% | — |
| NVAX | Novavax | $9.21 +2.56% | $1.51B | 53.2% | 52.7% | — |
| ARDX | Ardelyx | $6.11 -3.78% | $1.51B | 167.3% | 53.4% | — |
| FAE.MC | Faes Farma | $4.63 +0.33% | $1.44B | 16.5% | 39.6% | — |
| ATEC | Alphatec Holdings | $8.27 +0.49% | $1.27B | 109.6% | 8.8% | — |
| CNMD | Conmed Corporation | $37.26 +0.65% | $1.12B | 6.3% | 14.9% | — |
| CRVS | Corvus Pharmaceuticals | $12.61 -3.59% | $1.06B | 164.3% | 39.2% | — |
| MNKD | MannKind Corporation | $3.38 +2.11% | $1.04B | 121% | 26.9% | — |
| TNDM | Tandem Diabetes Care | $14.96 -5.04% | $1.03B | 104% | 25.3% | — |
| SDGR | Schrodinger | $13.30 +0.53% | $993.8M | 57% | 14.1% | — |
| OPK | OPKO Health | $1.27 -0.78% | $959M | 196.1% | 46.8% | — |
| USPH | US Physical Therapy | $62.03 -0.58% | $944M | 51% | 10.9% | — |
| EUZ.DE | Eckert and Ziegler | $15.02 -0.99% | $939.9M | 49.4% | 17.3% | — |
| EVT.DE | Evotec | $5.23 +2.95% | $928.8M | 23.2% | 27% | — |
| PSNL | Personalis | $8.47 +2.67% | $887M | 28.2% | 60.4% | — |
| CBAV.MC | Clinica Baviera | $53.80 -1.47% | $861.8M | — | 79.2% | — |
| XNCR | Xencor | $11.31 +0.35% | $838.5M | 152% | 37.3% | — |
| INMD | InMode | $13.74 -0.65% | $835.5M | 12.8% | 25.4% | — |
| CERT | Certara | $5.24 +1.35% | $815.2M | 45.4% | 8.4% | — |
| HSTM | HealthStream | $23.81 +0.59% | $695.6M | 34.4% | 42.5% | — |
| LBIRD.PA | Lumibird | $24.85 +1.84% | $548.3M | 18.7% | 90.5% | — |
| WEAV | Weave Communications | $5.71 +1.87% | $454.7M | 53.1% | 25.1% | — |
| EOLS | Evolent Health | $6.09 -5.58% | $401.1M | 140.8% | 33% | — |
| CCCC | C4 Therapeutics | $3.56 +1.14% | $393.6M | 225% | 85.8% | — |
| PACB | Pacific Biosciences | $1.22 -2.4% | $378.9M | 101.5% | 19.7% | — |
| REG1V.HE | Revenio Group | $14.06 -0.14% | $374.1M | 37.8% | 4.7% | — |
| FYB.DE | Formycon | $20.05 +1.98% | $354.3M | 98.8% | 27.4% | — |
| PRLD | Prelude Therapeutics | $4.27 -1.39% | $340.1M | — | 73.5% | — |
| EDIT | Editas Medicine | $2.76 +3.37% | $270.2M | 109.3% | 41.3% | — |
| FATE | Fate Therapeutics | $2.25 +7.14% | $262.3M | 139.5% | 85.9% | — |
| RNA | Avidity Biosciences | $13.09 +0.38% | $223.9M | 91% | 23.7% | — |
| SBS.DE | Stratec | $17.24 +1.17% | $209.6M | 50.8% | 5.4% | — |
| CRBU | Caribou Biosciences | $2.10 +5.53% | $208.3M | 471.4% | 44.3% | — |
| EMBC | Embecta Corp | $3.32 +0% | $197M | 20.5% | 4.3% | — |
| TMCI | Treace Medical Concepts | $2.78 -2.11% | $180.3M | 43.9% | 24.4% | — |
| VXRT | Vaxart | $0.64 -7.17% | $155M | 368.4% | 65.6% | — |
| HYPR | Hyperfine | $1.49 -0.67% | $147.9M | 45.4% | 56.7% | — |
| AMWL | Amwell | $8.00 +1.14% | $133.7M | -6.3% | 78.9% | — |
| NNOX | Nano-X Imaging | $1.84 -3.66% | $128M | 261.4% | 6.1% | — |
| SEER | Seer Bio | $1.79 +1.13% | $98.4M | 123.5% | 18.4% | — |
| HCAT | Health Catalyst | $1.29 +0% | $95.3M | 35.7% | 10% | — |
| TELA | Tela Bio | $0.89 -3.51% | $39.8M | 152.8% | 22.9% | — |
| CTSO | Cytosorbents Corporation | $0.46 +0.17% | $28.9M | 1039.3% | 2.7% | — |
| MARI.VI | Marinomed Biotech | $9.60 -2.54% | $19.2M | 426% | 8.1% | — |
Analysis and Context
This sector screener currently shows 82 stocks from the selected industry segment — updated daily. The average P/E ratio is 32.5x. The average revenue growth rate is 21.4%. Sectors move through cyclical phases strongly correlated with macro factors — interest rates, GDP growth, commodity prices, and regulatory environment all drive sector dynamics. Analysts see an average of 95.6% upside in these sector names. Compare metrics against the sector average to identify relative over- and undervaluations. Sector concentration increases portfolio risk — maintain adequate diversification across industries and business models.
Ready to invest?
Compare the best brokers for US and European stocks — fees, platforms and account types side by side.
Compare brokers →